• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与未添加佐剂的高剂量流感疫苗相比,AS03佐剂的极低剂量流感疫苗在BALB/c小鼠中诱导出独特的免疫反应。

AS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB/c Mice.

作者信息

Yam Karen K, Gupta Jyotsana, Winter Kaitlin, Allen Elizabeth, Brewer Angela, Beaulieu Édith, Mallett Corey P, Burt David S, Ward Brian J

机构信息

Department of Experimental Medicine, Research Institute of the McGill University Health Centre , Montreal, QC , Canada.

GSK Vaccines , Laval, QC , Canada.

出版信息

Front Immunol. 2015 Apr 29;6:207. doi: 10.3389/fimmu.2015.00207. eCollection 2015.

DOI:10.3389/fimmu.2015.00207
PMID:25972874
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4413846/
Abstract

During the 2009-2010 influenza pandemic, an adjuvanted, dose-sparing vaccine was recommended for most Canadians. We hypothesize that differences exist in the responses to AS03-adjuvanted, low antigen (Ag) dose versus unadjuvanted, full-dose vaccines. We investigated the relationship between Ag dose and the oil-in-water emulsion Adjuvant System AS03. BALB/c mice received two IM doses of AS03A or AS03B with exaggerated dilutions of A/Uruguay/716/2007 H3N2 split virion vaccine Ag. Immune responses were assessed 3 weeks after the booster. Unadjuvanted "high" (3 μg) and low-dose (0.03-0.003 μg) vaccines generated similar serum antibody titers and cytokine secretion patterns in restimulated splenocytes. Compared to unadjuvanted "high-dose" vaccination, both AS03A and AS03B-adjuvanted low-dose vaccines tended to elicit higher serum antibody titers, broader induction of cytokine secretion and generated more influenza-specific antibody secreting cells and cytokine-secreting CD4 and CD8 T cells in splenocytes. We show that varying Ag and/or AS03 dose in this influenza vaccination mouse model can strongly influence both the magnitude and pattern of the immune response elicited. These findings are highly relevant given the likelihood of expanded use of adjuvanted, dose-sparing vaccines and raise questions about the use of "standard" doses of vaccines in pre-clinical vaccine studies.

摘要

在2009 - 2010年流感大流行期间,建议大多数加拿大人接种一种含佐剂、可减少剂量的疫苗。我们推测,对AS03佐剂低抗原(Ag)剂量疫苗与无佐剂全剂量疫苗的反应存在差异。我们研究了Ag剂量与水包油乳剂佐剂系统AS03之间的关系。BALB/c小鼠接受了两剂肌肉注射的AS03A或AS03B,同时使用了A/乌拉圭/716/2007 H3N2裂解病毒颗粒疫苗Ag的过度稀释液。在加强免疫3周后评估免疫反应。无佐剂的“高”(3μg)剂量和低剂量(0.03 - 0.003μg)疫苗在再次刺激的脾细胞中产生了相似的血清抗体滴度和细胞因子分泌模式。与无佐剂的“高剂量”疫苗接种相比,AS03A和AS03B佐剂的低剂量疫苗都倾向于引发更高的血清抗体滴度、更广泛的细胞因子分泌诱导,并在脾细胞中产生更多的流感特异性抗体分泌细胞以及细胞因子分泌的CD4和CD8 T细胞。我们表明,在这种流感疫苗接种小鼠模型中改变Ag和/或AS03剂量可强烈影响所引发免疫反应的强度和模式。鉴于含佐剂、可减少剂量疫苗扩大使用的可能性,这些发现具有高度相关性,并对临床前疫苗研究中“标准”剂量疫苗的使用提出了疑问。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3eb/4413846/8a667220fa0d/fimmu-06-00207-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3eb/4413846/e3875a3125b8/fimmu-06-00207-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3eb/4413846/725abb50e87e/fimmu-06-00207-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3eb/4413846/87815c4b7ea5/fimmu-06-00207-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3eb/4413846/588af961fe98/fimmu-06-00207-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3eb/4413846/8a667220fa0d/fimmu-06-00207-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3eb/4413846/e3875a3125b8/fimmu-06-00207-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3eb/4413846/725abb50e87e/fimmu-06-00207-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3eb/4413846/87815c4b7ea5/fimmu-06-00207-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3eb/4413846/588af961fe98/fimmu-06-00207-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3eb/4413846/8a667220fa0d/fimmu-06-00207-g006.jpg

相似文献

1
AS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB/c Mice.与未添加佐剂的高剂量流感疫苗相比,AS03佐剂的极低剂量流感疫苗在BALB/c小鼠中诱导出独特的免疫反应。
Front Immunol. 2015 Apr 29;6:207. doi: 10.3389/fimmu.2015.00207. eCollection 2015.
2
Low hemagglutinin antigen dose influenza vaccines adjuvanted with AS03 alter the long-term immune responses in BALB/c mice.用AS03佐剂的低血凝素抗原剂量流感疫苗可改变BALB/c小鼠的长期免疫反应。
Hum Vaccin Immunother. 2017 Mar 4;13(3):561-571. doi: 10.1080/21645515.2016.1241360. Epub 2016 Oct 21.
3
Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.佐剂灭活流感 A(H3N2) 疫苗在小鼠中诱导更强的免疫原性,并在雪貂中提供比未佐剂灭活疫苗更高的保护。
Vaccine. 2014 Sep 29;32(43):5730-9. doi: 10.1016/j.vaccine.2014.08.029. Epub 2014 Aug 27.
4
Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.AS03 佐剂甲型 H5N1 流感疫苗加强免疫可改善异源加强免疫后的免疫应答动力学、幅度和持久性:一项双盲随机对照初级研究的开放性非随机扩展。
Vaccine. 2010 Jan 8;28(3):849-57. doi: 10.1016/j.vaccine.2009.10.017. Epub 2009 Oct 14.
5
Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.甲型 H1N1v 2009 流感疫苗单剂接种的免疫原性和安全性:含或不含 AS03A 佐剂的随机、双盲试验初步报告。
Vaccine. 2010 Feb 17;28(7):1740-5. doi: 10.1016/j.vaccine.2009.12.014. Epub 2009 Dec 22.
6
Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.3 至 9 岁儿童接种 H5N1 A/Vietnam/1194/2004(Clade 1)AS03 佐剂流感疫苗的免疫原性和安全性:一项 II 期、随机、开放、对照研究。
Pediatr Infect Dis J. 2010 Jun;29(6):e35-46. doi: 10.1097/INF.0b013e3181daf921.
7
AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.佐剂和非佐剂的 2009 年甲型流感(H1N1)疫苗在季节性流感疫苗接种和未接种的小鼠中诱导强烈的抗体反应。
Vaccine. 2010 Apr 19;28(18):3076-9. doi: 10.1016/j.vaccine.2010.02.050. Epub 2010 Mar 1.
8
Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years.AS03 佐剂 H1N1 2009 流感疫苗肌内接种后 6 个月的免疫应答安全性和持久性:6 个月至 17 岁日本儿童的开放性、随机试验。
Hum Vaccin Immunother. 2012 Jun;8(6):749-58. doi: 10.4161/hv.19684. Epub 2012 Apr 12.
9
Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months.在成人中单独或联合两种不同 AS03 佐剂制剂给予两剂 H5N1 流感抗原引发的免疫原性增强:15 个月时随机单异源加强剂量研究的结果。
Vaccine. 2011 Aug 26;29(37):6408-18. doi: 10.1016/j.vaccine.2011.04.072. Epub 2011 May 7.
10
Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.AS03 佐剂 A(H1N1)pmd09 疫苗与季节性三价疫苗同时或序贯接种于 61 岁及以上成年人的安全性和免疫原性:两项多中心随机试验数据。
Vaccine. 2012 Oct 5;30(45):6483-91. doi: 10.1016/j.vaccine.2012.07.081. Epub 2012 Aug 9.

引用本文的文献

1
In Vitro Assessment of a Doubly Adjuvanted Self-Emulsified Nanoemulsion as a Delivery Vehicle for Antigenic Proteins.双重佐剂自乳化纳米乳剂作为抗原蛋白递送载体的体外评估
Pharmaceutics. 2025 Jul 2;17(7):870. doi: 10.3390/pharmaceutics17070870.
2
Fusion of Complement Fragment C3d Enhances Germinal Center Responses to HIV-1 Envelope Glycoproteins.补体片段C3d融合增强生发中心对HIV-1包膜糖蛋白的反应。
bioRxiv. 2025 Jul 1:2025.06.28.661730. doi: 10.1101/2025.06.28.661730.
3
Assessment of Models of the Human Buccal Mucosa for Vaccine and Adjuvant Development.

本文引用的文献

1
Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.佐剂灭活流感 A(H3N2) 疫苗在小鼠中诱导更强的免疫原性,并在雪貂中提供比未佐剂灭活疫苗更高的保护。
Vaccine. 2014 Sep 29;32(43):5730-9. doi: 10.1016/j.vaccine.2014.08.029. Epub 2014 Aug 27.
2
Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older.在一项针对 65 岁及以上成年人的随机试验中,三价流感疫苗与 AS03 佐剂联合使用可诱导出更强的抗原特异性 CD4+ T 细胞应答。
BMC Infect Dis. 2014 Jul 30;14:425. doi: 10.1186/1471-2334-14-425.
3
用于疫苗和佐剂开发的人体颊黏膜模型评估
Mol Pharm. 2025 Jun 2;22(6):2868-2880. doi: 10.1021/acs.molpharmaceut.4c01186. Epub 2025 Mar 26.
4
Developing a universal multi-epitope protein vaccine candidate for enhanced borna virus pandemic preparedness.开发一种通用多表位蛋白疫苗候选物以加强对博尔纳病毒大流行的防范。
Front Immunol. 2024 Dec 5;15:1427677. doi: 10.3389/fimmu.2024.1427677. eCollection 2024.
5
Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies.老年人群疫苗研究进展:从免疫衰老的影响到接种策略
NPJ Vaccines. 2024 Apr 10;9(1):77. doi: 10.1038/s41541-024-00874-4.
6
Construction of Adhesin-Exposed Synthetic Cells for Preventing Systemic Fungal Infection.用于预防全身性真菌感染的暴露黏附素合成细胞的构建
Vaccines (Basel). 2023 Sep 25;11(10):1521. doi: 10.3390/vaccines11101521.
7
The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.佐剂类型对 RBD/N 鸡尾酒抗原作为 SARS-CoV-2 病毒疫苗候选物的免疫原性的影响。
Microbiol Spectr. 2023 Jun 15;11(3):e0256422. doi: 10.1128/spectrum.02564-22. Epub 2023 May 18.
8
Effective adjuvantation of nanograms of influenza vaccine and induction of cross-protective immunity by physical radiofrequency adjuvant.物理射频佐剂有效增强纳克级流感疫苗并诱导交叉保护免疫。
Sci Rep. 2022 Dec 8;12(1):21249. doi: 10.1038/s41598-022-25605-4.
9
Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant.没食子酸表没食子儿茶素酯作为一种新型疫苗佐剂。
Front Immunol. 2021 Nov 12;12:769088. doi: 10.3389/fimmu.2021.769088. eCollection 2021.
10
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.接种 SARS-CoV-2 刺突蛋白疫苗产生的保护性抗体在非人灵长类动物挑战后在肺部增强。
Sci Transl Med. 2021 Aug 18;13(607). doi: 10.1126/scitranslmed.abi4547. Epub 2021 Jul 27.
T cell mediated immunity to influenza: mechanisms of viral control.
T 细胞介导的流感免疫:病毒控制机制。
Trends Immunol. 2014 Aug;35(8):396-402. doi: 10.1016/j.it.2014.06.004. Epub 2014 Jul 16.
4
High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine.在接受灭活裂解佐剂(AS03A)流感疫苗的HIV血清阳性受种者中可实现高水平的抗体亲和力。
J Clin Immunol. 2014 Aug;34(6):655-62. doi: 10.1007/s10875-014-0054-z. Epub 2014 May 14.
5
Vaccine adjuvant safety: the elephant in the room.疫苗佐剂安全性:不容忽视的重大问题。
Expert Rev Vaccines. 2013 Jul;12(7):715-7. doi: 10.1586/14760584.2013.811198.
6
Genomic responses in mouse models poorly mimic human inflammatory diseases.小鼠模型中的基因组反应与人类炎症性疾病的反应相差很大。
Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3507-12. doi: 10.1073/pnas.1222878110. Epub 2013 Feb 11.
7
Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice.新型 Matrix-M™ 佐剂具有免疫增强特性,可增强小鼠对流感疫苗的免疫应答。
Vaccine. 2013 Mar 25;31(13):1725-33. doi: 10.1016/j.vaccine.2013.01.039. Epub 2013 Feb 4.
8
Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine.部分幼儿在接种两剂含佐剂的2009年甲型H1N1大流行性流感病毒疫苗后出现的异常IgG亲和力模式。
Clin Vaccine Immunol. 2013 Apr;20(4):459-67. doi: 10.1128/CVI.00619-12. Epub 2013 Jan 23.
9
Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.含全剂量 MF59(®)佐剂的季节性流感疫苗具有优越的免疫原性:一项在老年人中进行的剂量探索性临床试验结果。
Hum Vaccin Immunother. 2012 Feb;8(2):216-27. doi: 10.4161/hv.18445. Epub 2012 Feb 1.
10
Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.AS03 的研制与评价:一种含 α-生育酚和角鲨烯的油包水乳剂佐剂系统。
Expert Rev Vaccines. 2012 Mar;11(3):349-66. doi: 10.1586/erv.11.192.